Thursday, December 6, 2012

Coated aspirin

  • Coated Aspirin Heart Benefits Questioned

    Coated aspirin may lose some of its cardiovascular benefits because it takes longer for the drug to dissolve into the bloodstream, a new study suggested.

  • Common aspirin coating reported to reduce its effectiveness

    Aspirin is a common over-the-counter medication used to reduce pain and inflammation; a low dose formulation (81 mg) is also taken to reduce the risk of heart attack and stroke.

  • Aspirin coating leads to 'pseudo' resistance

    Coated aspirin adds cost to treatment without any clear benefit, says Garret FitzGerald of the University of Pennsylvania, and may also may lead to the false diagnosis of aspirin resistance and the failure to provide patients with an effective therapy ...

  • Aspirin Resistance a False Diagnosis for Heart Care

    Bayer, which contributed funding for the research, said a delayed uptake of coated aspirin "would not be unexpected," in an e-mail yesterday.

  • New aspirin study reveals that coating may mask heart benefits

    Advertisement. Tuesday, the results of a new aspirin study were published in the journal Circulation; aspirin is known to prevent heart attacks and strokes, but this new aspirin study revealed that the coating on aspirin may mask the benefits that ...

  • Coated Pills May Limit Benefits of Aspirin, Study Finds

    Researchers at the University of Pennsylvania say if you need aspirin -- because you've had a heart attack, blocked arteries or other complications -- you're better off taking a pill that's not coated.

  • Aspirin Resistance Is Extremely Rare

    Lead researcher, FitzGerald and team recruited 400 healthy volunteers and screened their responses to a single oral immediate release or enteric coated aspirin, with a dose of 325 mg. Participants who had appeared aspirin resistant once were tested ...

  • Coated Aspirin Not as Effective For Heart Attack Prevention

    They concluded that it wasn't the drug itself but its coating to buffer the stomach from upset that interfered with the heart-protective effects, the New York Times reports.

  • True aspirin resistance extremely rare

    "Secondly, there is no rational basis for selecting coated aspirin over immediate release (uncoated) aspirin which is cheaper; it hasn't been shown to protect the stomach and may lead to a false call of aspirin resistance," he said.

  • Pozen's Safer Aspirin Pipeline Looks Promising

    Trial participants were randomly assigned to treatment with either PA32540 or 325 mg enteric-coated aspirin once daily. The primary endpoint, a significant reduction in the cumulative incidence of gastric ulcers following administration of PA32540 ...

  • Health Highlights: Dec. 5, 2012

    Coating on aspirin may interfere with the way the drug is absorbed by the body, which may explain why some people appear to be resistant to its heart attack and stroke prevention benefits, a new study says.

  • New Study Highlights Importance of Testing for Aspirin Effect with FDA-Cleared ...

    In the Grosser, et al. study, University of Pennsylvania researchers looking at 400 healthy volunteers and the impact of enteric coated versus uncoated aspirin, narrowly focused on a rare, genetic resistance to the effect of taking aspirin and ignored ...

  • Broomfield-based Corgenix defends aspirin-resistance kits after study

    The study found that the coated aspirin had varying absorption rates that may have made some appear "resistant," while every participant responded to immediate-release aspirin, providing no evidence of a pharmacological resistance.

  • AHA: PPI-Aspirin Pill Eases GI Ulcers in Heart Patients

    At 3 months, 1.7% of the 521 patients randomly assigned to treatment with PA32540 had developed endoscopically-detected ulcers compared with 6.7% of the patients taking the enteric-coated aspirin alone (P<0.001). And at 6 months, 3.2% of patients ...

  • Aspirin alternative to ward off cardiovascular disease could improve patient ...

    Two Phase 3 clinical trials enrolled 1,049 subjects in double blind studies over 24 months comparing enteric-coated aspirin with Pozen's aspirin alternative, PA32540.The primary endpoint of the study was how many incidents of gastric ulcers there were ...

  • POZEN's CEO Discusses Q3 2012 Results - Earnings Call Transcript

    As we announced earlier this week and in our press release this morning, both Phase 3 studies achieved their individual primary endpoints as patients on PA32540 experienced fewer gastric ulcers compared to those taking enteric-coated aspirin 325 mg ...

  • POZEN INC. : POZEN Announces Positive Results for the PA8140-102 ...

    ... results from a Phase 1 study, PA8140-102, demonstrated that PA8140, POZEN's proprietary combination of aspirin (81 mg) and omeprazole (40 mg), had comparable bioavailability relative to the reference listed product, enteric-coated (EC) aspirin (81 mg).

  • Non-Melting Chocolate Invented By Cadbury Stays Solid In 104 Degree Heat

    At last! Hot and humid countries without the full benefit of air conditioning and refrigeration can now have Cadbury Creamed Eggs!

  • Aspirin enough to prevent blood clots

    They were randomly allocated to receive either low-dose enteric coated aspirin or a matching placebo. On average, participants were followed for three years.

  • Study shows aspirin can help prevent dangerous blood clots

    Participants were randomly allocated to receive either low dose enteric coated aspirin 100mg daily or a matching placebo. On average, participants were followed for three years.

No comments:

Post a Comment